Global Antithrombotic Drugs Market, By Type (Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin, Rivaroxaban), Drug Class (Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants, Others), Indication (Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE), Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Hypercoagulability, irregular blood flow, and damage to blood vessel endothelial cells are the three main causes of thrombosis. Genetic disorders, inactivity, smoking, blood vessel disease, pregnancy, and obesity are all contributing factors. Various forms of thrombosis therapies are currently available on the market. Anticoagulants, commonly known as blood thinners, are the first-line treatment for thrombosis. These medications are primarily used to break or dissolve clots through enzymatic action. The main thrombosis medications on the market include Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin, Rivaroxaban, and Warfarin. Heparin and warfarin medications are predicted to account for the largest market share among all drugs over the forecast period.
Data Bridge Market Research analyses that the antithrombotic drugs market was valued at USD 41,697.49 million in 2021 and is expected to reach USD 76,722.98 million by 2029, registering a CAGR of 7.92% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin, Rivaroxaban), Drug Class (Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants, Others), Indication (Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE), Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED (Japan), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Aspen Holdings (South Africa)
|
|
Market Opportunities
|
|
Market Definition
Antithrombotic medication helps to prevent thrombus or clot development. Antithrombotic and anticoagulant medications lower the body's ability to form blood clots. These medicines work by blocking the liver from producing vitamin K. Antithrombotic agents include antiplatelet, anticoagulant, and thrombolytic agents, which work on different coagulation pathways. Antithrombotic medicines can be used to treat arterial and venous thrombosis, respectively.
Antithrombotic Drugs Market Dynamics
Drivers
- Increasing prevalence of chronic diseases
The increased prevalence of chronic illness such as cancer, hypertension and cardiac related disorders will fuel industry growth. Cardiovascular diseases (CVDs) are the largest cause of death worldwide, claiming the lives of an estimated 17.9 million people each year. Heart attacks and strokes account for more than four out of every five CVD deaths, with one-third of these deaths occurring before the age of 70.
- Rising number geriatric population
The anti-thrombotic medicines market grew due to the ageing demographic profiles of most countries. According to estimates based on Population Reference Bureau statistics, the number of individuals over 65 in the world increased by 33% between 2014 and 2017, from under 450 million to 601 million. During the forecast period, this tendency is expected to continue. In Japan, the proportion of seniors is predicted to rise from 24% in 2012 to 40% in 2050. The ageing population has increased the number of people who suffer from cardiovascular diseases, which are a leading cause of death.
Furthermore, surging number of government initiatives to spread awareness will result in the expansion of antithrombotic drugs market. Along with this, sedentary lifestyle of people and favourable reimbursement policies will enhance the growth rate of the market. Another significant factor influencing the growth rate of antithrombotic drugs market is the rising healthcare expenditure which helps in improving its infrastructure.
Opportunities
- Growing demand for NOACS
Increased demand for NOACS, as well as government healthcare policies and programmes, are key drivers of growth in the worldwide antithrombotic medicines market. The market is growing due to the rising acceptance of NOACs. To prevent and cure thrombosis, NOACs target either thrombin or factor Xa. They demonstrate fast activity and do not necessitate constant supervision. The administrations of the various regions are taking steps to improve the health of the country. This will provide new market opportunities.
Moreover, the market's growth is fueled by an increase in the number of research and development activities for the new drug development and new product launches. These factors will provide beneficial opportunities for the antithrombotic drugs market growth.
Restraints/Challenges
- Side effects linked with antithrombotic drugs
As side effects are primary consideration for thrombosis patients, doctors frequently try to offer alternative therapies to their patients, and this factor is anticipated to hinder the market's growth throughout the projection period. Higher bruising, red or pink coloured urine, more bleeding than normal in female menstrual periods, pain, increased risk of pregnancy difficulties, and a change in temperature are the most common antithrombotic medication adverse effects. If a woman is pregnant while using warfarin, for instance, the medicine can cause foetal mortality.
On the other hand, high cost associated with the drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the antithrombotic drugs market. Additionally, lack of awareness among people and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This antithrombotic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antithrombotic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Antithrombotic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Antithrombotic Drugs Market
Due to the rapid speed of research, COVID-19 infection is predicted to have a significant influence on the antithrombotic drugs market. As per a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are currently underway to assess the potential of antithrombotic drugs in COVID-19 patients, and research on parenteral administration strategies for these drugs is being conducted for use in critically ill COVID-19 patients. Furthermore, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose antithrombotic drugs, according to a World Health Organization Update published in January 2021. As a result, antithrombotic drugs demand surged during COVID-19.
Recent Development
- In December 2020, Natco Pharma had announced the launch of an antithrombotic drugs medication named Rivaroxaban (RPIGAT). Rivaroxaban is an antithrombotic drugs drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.
Global Antithrombotic Drugs Market Scope
The antithrombotic drugs market is segmented on the basis of type, drug class, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Apixaban
- Debigatran
- Edoxaban
- Fondaparinux
- Heparin
- Rivaroxaban
Indication
- Atrial Fibrillation
- Stroke
- Deep vein thrombosis (DVT)
- Pulmonary Embolism (PE)
- Others
Drug Class
- Thrombolytic Drugs
- Anti-Platelet Drugs
- Anticoagulants
- Others
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Antithrombotic Drugs Market Regional Analysis/Insights
The antithrombotic drugs market is analysed and market size insights and trends are provided by country, type, drug class, indication, route of administration, end-users and distribution channel as referenced above.
The countries covered in the antithrombotic drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the antithrombotic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing cardiac and cancer diseases and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.
Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to surging number of geriatric population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Antithrombotic Drugs Market Share Analysis
The antithrombotic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antithrombotic drugs market.
Some of the major players operating in the antithrombotic drugs market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Eisai Co., Ltd. (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Aspen Holdings (South Africa)
SKU-